Evaluating the Safety and Immune Response to a Dengue Virus Vaccine in Healthy Adults

ClinicalTrials.gov ID: NCT01931176

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01931176. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 6:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Evaluation of the Safety and Immunogenicity of rDEN2Δ30-7169, a Live Attenuated Monovalent Dengue Virus Vaccine

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Dengue viruses can cause dengue fever and other more serious illnesses. The purpose of this study is to evaluate the safety and immune response to a dengue virus vaccine.

Study identification

NCT ID: NCT01931176
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Enrollment: 14 participants

Conditions and interventions

Conditions

Dengue

Interventions

rDEN2Δ30-7169 vaccine Biological
Placebo Biological

Biological

Eligibility (public fields only)

Age range: 18 Years to 50 Years
Sex: All
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 2013 (Type not available)
Primary completion: Dec 2014 (Actual)
Completion: May 2015 (Actual)
Last update posted: Dec 15, 2015

2013 – 2015

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
John Hopkins Bloomberg School of Public Health - Center for Immunization Research (CIR)	Baltimore	Maryland	21205	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01931176, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 15, 2015 · Synced Nov 12, 2026